Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BCWFQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IPH45
|
|||||
| Synonyms |
IPH45; IPH4502
Click to Show/Hide
|
|||||
| Organization |
Innate Pharma (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-Nectin-4 antibody
|
Antibody Info | ||||
| Antigen Name |
Nectin-4 (NECTIN4)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable hydrophilic linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
ADC-specific functional property(2027 Update)
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
IPH4502 demonstrates strong bystander killing effect in vivo, and high internalization efficiency in vitro in comparison to other Nectin-4 ADCs.
|
[1]
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Key inclusion: Nectin-4-expressing unresectable/metastatic solid tumors, prior systemic therapy, measurable disease (RECIST 1.1), adequate organ function. Key exclusion: brain metastases, active/latent infections, ILD, recent thromboembolic/cardiovascular events, recent surgery or immunosuppressive therapy, CYP3A4 modifiers, or live vaccines within specified periods.
Click to Show/Hide
|
||||
| Administration Dosage |
Part 1 (dose escalation) and Part 2 (dose optimization)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06781983 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors | ||||
| Primary Endpoint |
The study evaluates safety and tolerability, monitoring adverse events (AEs, SAEs, TEAEs) and dose-limiting toxicities (DLTs) over 24 months from first dose through treatment and follow-up.
|
||||
| Other Endpoint |
Pharmacokinetic analysis includes assessing Cmax, AUC, and ADA incidence against IPH4502, alongside preliminary antitumor activity metrics (ORR, DoR, PFS) over 24 months from informed consent through treatment and follow-up.
|
||||
References